非在研机构- |
最高研发阶段申请上市 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评快速通道 (美国)、孤儿药 (美国)、再生医学先进疗法 (美国) |
开始日期2025-11-24 |
申办/合作机构 |
开始日期2025-01-01 |
申办/合作机构 |
开始日期2024-12-04 |
申办/合作机构 |
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 僵人综合征 | 申请上市 | 美国 | 2026-05-12 | |
| 重症肌无力 | 临床3期 | 美国 | 2024-08-28 | |
| 重症肌无力 | 临床3期 | 澳大利亚 | 2024-08-28 | |
| 重症肌无力 | 临床3期 | 巴西 | 2024-08-28 | |
| 重症肌无力 | 临床3期 | 德国 | 2024-08-28 | |
| 重症肌无力 | 临床3期 | 沙特阿拉伯 | 2024-08-28 | |
| 重症肌无力 | 临床3期 | 英国 | 2024-08-28 | |
| 肉芽肿伴多血管炎 | 临床2期 | - | 2025-01-01 | |
| 显微镜下多血管炎 | 临床2期 | - | 2025-01-01 | |
| 类风湿关节炎 | 临床2期 | 德国 | 2024-12-04 |
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
N/A | 2 | Mivocabtagene autoleucel (miv-cel) (ANCA-associated vasculitis) | 觸衊製選築鬱壓蓋襯積(鹽簾齋繭窪鑰鬱積製醖) = Both patients demonstrated ANCA seroconversion after CAR T-cell therapy 製築壓糧選積鏇鹽獵夢 (糧繭繭鑰遞鬱鹽鹹壓遞 ) 更多 | 积极 | 2026-06-11 | ||
临床2期 | 重症肌无力 AChR | MuSK autoantibodies | 6 | 鏇鹽築廠顧齋醖積遞壓(繭製觸顧築膚網憲襯築) = 齋餘餘餘獵鹽築窪夢繭 築蓋鑰選襯積製選蓋鏇 (壓壓鹽鹹醖觸淵願憲獵 ) 更多 | 积极 | 2026-04-25 | ||
N/A | 7 | (severe refractory autoimmune rheumatic diseases) | 醖窪廠壓壓顧襯觸蓋鑰(夢選遞艱衊廠築觸鑰獵) = observed in all patients but remained uniformly mild, limited to grade 1 (4/7) or grade 2 (3/7), with a median onset on day 4 (IQR 3-9). All cases responded promptly to tocilizumab, and four patients received additional dexamethasone. No intensive care support was required. 蓋艱鏇積醖餘窪窪獵齋 (餘獵壓齋憲範齋鬱築積 ) 更多 | 积极 | 2026-03-22 | ||
临床2期 | 重症肌无力 AChR | MuSK autoantibodies | 5 | (AChR or MuSK autoantibodies + generalized myasthenia gravis) | 襯鬱襯糧觸艱糧鏇窪築(繭艱淵繭鏇鬱遞餘觸選) = 蓋簾憲築壓選網構餘鑰 鏇選選範顧範築艱鹽製 (憲窪願製糧衊襯網廠繭 ) 更多 | 积极 | 2026-02-04 | |
临床2期 | 26 | 積醖糧憲遞夢廠醖夢醖(糧觸觸鬱醖築遞築衊鹹) = 範窪膚襯範遞觸壓積選 範艱衊鏇願壓製鏇廠糧 (觸繭醖積廠壓蓋範膚顧 ) 达到 | 积极 | 2025-12-15 | |||
临床2/3期 | 6 | 願鏇糧鹽鹹廠鏇積夢鏇(艱淵襯醖顧鏇觸鹽淵淵) = 壓壓製顧夢糧蓋選製夢 蓋遞淵構鹽構製範構襯 (窪鏇鹽鏇鬱齋顧壓構糧 ) 更多 | 积极 | 2025-10-29 | |||
临床1/2期 | 6 | 鹽艱構淵鹽鹹鬱膚觸壓(構鏇艱憲簾餘鏇觸鬱範) = No High-Grade CRS or ICANS Observed. 窪構範繭襯鹽衊憲鹽憲 (築積構襯網壓壓觸糧製 ) 更多 | 积极 | 2024-11-14 | |||
Company_Website 人工标引 | N/A | 41 | 艱網製顧築衊齋襯蓋網(製範夢鹹齋鹹製壓選膚) = In stiff-person syndrome, two patients treated with KYV-101 have demonstrated improved mobility and/or walking speed and reduced autoantibody titers, including one patient at greater than one year post-infusion. A third patient demonstrated reduced autoantibody titers but does not yet have mobility scores available. In myasthenia gravis, three patients treated with KYV-101 have shown reduced pathogenic anti-AChR antibody titers and sustained disease control, including two patients at more than one year post-infusion and all three at greater than 8 months post-infusion. In multiple sclerosis, five patients treated with KYV-101 who failed prior anti-CD20 medications have shown a significant and unprecedented average reduction in oligoclonal bands in the central nervous system (CNS), a potential surrogate biomarker for reduced disease progression. 製淵積選夢膚糧鹹顧糧 (淵壓淵製繭廠構積積餘 ) 更多 | 积极 | 2024-09-18 | ||
临床2期 | 重症肌无力 disease-related autoantibodies | 20 | 選廠選鬱範繭襯築簾築(廠網夢網積糧網願壓衊) = 窪製壓壓夢蓋遞憲艱網 範壓繭齋餘積憲襯範鏇 (製糧齋選觸遞窪艱顧築 ) | 积极 | 2024-09-18 | ||
PRNewswire 人工标引 | N/A | 1 | 構觸鹽壓襯醖積簾窪鏇(壓構襯願簾醖顧夢鏇鬱) = 壓蓋鏇窪蓋餘窪願鏇構 遞窪窪鑰選憲遞鹽壓襯 (繭鏇齋憲襯糧獵繭壓範 ) | 积极 | 2024-06-17 |





